← Back to All US Stocks

Quantumzyme Corp. (QGAI) Stock Fundamental Analysis & AI Rating 2026

QGAI Industrial Organic Chemicals NV CIK: 0001663038
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2026-01-31
STRONG SELL
98% Conf
Pending
Analysis scheduled

📊 QGAI Key Takeaways

Revenue: $0.0
Net Margin: N/A
Free Cash Flow: $-55.7K
Current Ratio: 0.00x
Debt/Equity: N/A
EPS: $-0.11
AI Rating: STRONG SELL with 98% confidence
Quantumzyme Corp. (QGAI) receives a STRONG SELL rating with 98% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $0, Quantumzyme Corp. demonstrates mixed fundamentals in the Materials sector. Below is our complete QGAI stock analysis for 2026.

Is Quantumzyme Corp. (QGAI) a Good Investment?

Claude

QGAI is technically insolvent with negative stockholders equity of -$418.3K and zero revenue generation. The company has only $59 in cash against $418.4K in liabilities and is burning cash with -$43.8K in operating cash flow, indicating imminent insolvency without immediate capital injection.

Why Buy Quantumzyme Corp. Stock? QGAI Key Strengths

Claude
  • + Minimal technical assets exist ($59 cash)
  • + Classified in industrial chemicals sector which has market demand
  • + No recent insider selling activity indicates insiders may be resigned

QGAI Stock Risks: Quantumzyme Corp. Investment Risks

Claude
  • ! Negative stockholders equity (-$418.3K) - company is balance sheet insolvent
  • ! Zero revenue with -$4.4M net loss - no business operations
  • ! Current ratio of 0.00x - unable to meet short-term liabilities of $418.4K with $59 cash
  • ! Negative operating cash flow (-$43.8K) - actively burning capital
  • ! Free cash flow deeply negative (-$55.7K) - value destruction with no recovery path
  • ! Zero insider filings in 90 days - lack of confidence or activity

Key Metrics to Watch

Claude
  • * Stockholders equity trend toward positive territory
  • * Revenue generation and operating breakeven achievement
  • * Cash position and runway until capital depletion
  • * Form 4 insider activity indicating conviction or exit

Quantumzyme Corp. (QGAI) Financial Metrics & Key Ratios

Revenue
$0.0
Net Income
$-4.4M
EPS (Diluted)
$-0.11
Free Cash Flow
$-55.7K
Total Assets
$59.0
Cash Position
$59.0

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

QGAI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -7,422,923.7%
FCF Margin N/A

QGAI vs Materials Sector: How Quantumzyme Corp. Compares

How Quantumzyme Corp. compares to Materials sector averages

Net Margin
QGAI 0.0%
vs
Sector Avg 10.0%
QGAI Sector
ROE
QGAI 0.0%
vs
Sector Avg 14.0%
QGAI Sector
Current Ratio
QGAI 0.0x
vs
Sector Avg 1.6x
QGAI Sector
Debt/Equity
QGAI 0.0x
vs
Sector Avg 0.6x
QGAI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Quantumzyme Corp. Stock Overvalued? QGAI Valuation Analysis 2026

Based on fundamental analysis, Quantumzyme Corp. has mixed fundamental signals relative to the Materials sector in 2026.

Return on Equity
N/A
Sector avg: 14%
Net Profit Margin
N/A
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Quantumzyme Corp. Balance Sheet: QGAI Debt, Cash & Liquidity

Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
N/A
Debt/Assets
709,154.2%
Interest Coverage
-3.10x
Long-term Debt
N/A

QGAI Revenue & Earnings Growth: 5-Year Financial Trend

QGAI 5-year financial data: Year 2017: Revenue $128.1K, Net Income -$3.7K, EPS N/A. Year 2018: Revenue $128.1K, Net Income -$32.9K, EPS N/A. Year 2025: Revenue $0, Net Income -$178.6K, EPS $-0.01.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Quantumzyme Corp.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.01 indicates the company is currently unprofitable.

QGAI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

QGAI Quarterly Earnings & Performance

Quarterly financial performance data for Quantumzyme Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2026 N/A -$29.8K $0.00
Q1 2026 N/A -$49.9K $0.00
Q3 2025 N/A -$6.0K N/A
Q1 2018 $30.6K -$2.1K N/A
Q1 2017 $30.1K -$1.9K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Quantumzyme Corp. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$43.8K
Cash generated from operations
Capital Expenditures
$11.9K
Investment in assets
Dividends
None
No dividend program

QGAI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Quantumzyme Corp. (CIK: 0001663038)

📋 Recent SEC Filings

Date Form Document Action
Mar 19, 2026 10-Q qtzm_10q.htm View →
Feb 13, 2026 8-K qtzm_8k.htm View →
Jan 7, 2026 8-K qtzm_8k.htm View →
Dec 15, 2025 10-Q qtzm_10q.htm View →
Nov 17, 2025 10-K/A qtzm_10ka.htm View →

Frequently Asked Questions about QGAI

What is the AI rating for QGAI?

Quantumzyme Corp. (QGAI) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.

What are QGAI's key strengths?

Claude: Minimal technical assets exist ($59 cash). Classified in industrial chemicals sector which has market demand.

What are the risks of investing in QGAI?

Claude: Negative stockholders equity (-$418.3K) - company is balance sheet insolvent. Zero revenue with -$4.4M net loss - no business operations.

What is QGAI's revenue and growth?

Quantumzyme Corp. reported revenue of $0.0.

Does QGAI pay dividends?

Quantumzyme Corp. does not currently pay dividends.

Where can I find QGAI SEC filings?

Official SEC filings for Quantumzyme Corp. (CIK: 0001663038) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is QGAI's EPS?

Quantumzyme Corp. has a diluted EPS of $-0.11.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is QGAI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Quantumzyme Corp. has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is QGAI stock overvalued or undervalued?

Valuation metrics for QGAI: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy QGAI stock in 2026?

Our dual AI analysis gives Quantumzyme Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is QGAI's free cash flow?

Quantumzyme Corp.'s operating cash flow is $-43.8K, with capital expenditures of $11.9K.

How does QGAI compare to other Materials stocks?

Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio 0.00 (avg: 1.6).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2026-01-31 | Powered by Claude AI